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Purpose: The aim of this study was to investigate the molecular basis of childhood
glaucoma in Switzerland to recommend future targeted genetic analysis in the Swiss
population.
Methods: Whole-exome sequencing and copy number variation (CNV) analysis was
performed in a Swiss cohort of 18 patients from14 unrelated families. Identified variants
were validated by Sanger sequencing and multiplex ligation-dependent probe amplifi-
cation. Breakpoints of structural variants were determined by a microarray. A minigene
assay was conducted for functional analysis of a splice site variant.
Results: A diagnosis of primary congenital glaucomawasmade in 14 patients, of which
six (43%) harbored pathogenic variants in CYP1B1, one (7%) a frameshift variant in
FOXC1, and seven (50%) remained without a genetic diagnosis. Three patients were
diagnosed with glaucoma associated with nonacquired ocular anomalies, of which
two patients with mild ocular features of Axenfeld-Rieger syndrome harbored a FOXC1
duplication plus an additional FOXC1 missense variant, and one patient with a Barkan
membrane remained without genetic diagnosis. A diagnosis of juvenile open-angle
glaucoma was made in one patient, and genetic analysis revealed a FOXC1 duplication.
Conclusions: Sequencing of CYP1B1 and FOXC1, as well as analysis of CNVs in FOXC1,
should be performed before extended gene panel sequencing.
Translational Relevance: The identification of the molecular cause of childhood
glaucoma is a prerequisite for genetic counseling and personalized care for patients and
families.
Introduction
Childhood glaucoma is characterized by progressive
and irreversible damage to retinal ganglion cells and
may lead to blindness. Developmental abnormalities of
the anterior segment of the eye can result in impaired
outflow of aqueous humor through the trabecu-
lar meshwork into Schlemm’s canal.1 Childhood
glaucoma classification distinguishes primary congeni-
tal glaucoma (PCG) and juvenile open angle glaucoma
(JOAG) from secondary types of glaucoma depending
on the presence of acquired/ non-acquired ocular or
systemic features.2 The primary form (PCG), charac-
terized by isolated trabeculodysgenesis and an early
disease onset, can present with tearing, photopho-
bia, and blepharospasm. An enlarged globe (buphthal-
mos), increased cup-to-disc-ratio, corneal edema, and
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breaks in the Descemet’s membrane (Haab’s striae) are
frequent clinical findings. In JOAG disease onset is
between the ages of four and 40 years, presenting with
a normal appearing anterior angle and without corneal
or globe enlargement.2 Secondary forms of the disease
include glaucoma associated with Peters’ anomaly,
aniridia, ectopia lentis, and a number of syndromes
including Axenfeld-Rieger syndrome (ARS).3 Variable
presence of ocular features of ARS such as iris
processes, posterior embryotoxon, corectopia, and iris
hypoplasia, may cause the clinical distinction from
PCG to be challenging.4
Type and incidence of childhood glaucoma varies
according to population studied and degree of parental
consanguinity (e.g. the incidence of PCG ranges
from 1:1250 to 1:30,000).5–7 Ma et al.8 have recently
presented an overview of genes associated with
anterior segment disease and associated overlap-
ping phenotypes. These include CYP1B1, FOXC1,
PAX6, PITX2, FOXE3, PITX3, B3GLCT, COL4A1,
PXDN, CPAMD8, LTBP2, all of which are associ-
ated with anterior segment anomalies which may lead
to secondary glaucoma; of these, CYP1B1, FOXC1,
and LTBP2 are specifically associated with PCG. The
gene TEK is also associated with PCG. Souma et al.9
observed compromised aqueous humor outflow inTek-
null-mice, but there was markedly variable expressivity
in human patients.9 A review of PCG-associated genes
is provided in the Supplementary Material. The list for
potential childhood glaucoma-associated genes can be
extended for syndromic types of childhood glaucoma
and the autosomal dominant JOAG gene MYOC.3,10
However, a genetic cause remains unknown in a large
proportion of patients.1
In Switzerland, the genotype distribution of child-
hood glaucoma is unknown. Genetic analyses are not
always paid for by health insurance providers, there-
fore in these circumstances the costs must be borne by
the families. Medical treatment and screening strate-
gies would be improved by knowledge of the under-
lying genetic causes of the disease. Thus our aim was
to characterize a Swiss childhood glaucoma cohort by
filtering whole-exome sequencing (WES) data with an
extended gene list based on the results of a current liter-
ature search; correlate genotype with clinical parame-
ters; and, on the basis of our findings, evaluate time-




Patients with bilateral childhood glaucoma were
recruited from the Departments of Ophthalmology
at the University Hospital Zurich and University
Hospital Basel, together with their families. Diagno-
sis of PCG, JOAG, or glaucoma associated with non-
acquired ocular anomalies was made based on the
Childhood Glaucoma Research Network Classifica-
tion System Flowchart.2 Clinical examination results
were obtained from patient records from the first
and last visits: (1) presence of buphthalmos, (2)
anterior segment morphology including presence of
Haab’s striae and/or iris abnormalities and horizon-
tal corneal diameter, (3) optic disc cupping, (4) best-
corrected distance or near visual acuity assessed with
age-appropriate methods, (5) IOP measured using
Tonopen, Goldmann, or Perkins tonometer according
to the patient’s age, either awake or under anesthe-
sia, and (6) retinal nerve fiber layer (RNFL) thick-
ness quantified using optical coherence tomography,
when possible. The presence of a systemic disease
or malformation and/or intellectual disability was
noted. Number and type of surgeries were analyzed
across the entire treatment period. Trabeculectomy and
glaucoma drainage device implantation were catego-
rized as fistulating surgeries. Treatment success was
defined according to the Tube Versus Trabeculec-
tomy Study.11 Demographic parameters and informa-
tion about family history were recorded after direct
questioning of the families. Affected family members
were included in the study and their data were also
extracted from their patient records. Blood samples
were collected from all patients and their parents, as
well as siblings (if available). Ethical approval was
obtained (Cantonal Ethics Committee of Zurich, Ref-
No. 2019-00108), and patients or guardians provided
written informed consent. The study was conducted in
accordance with the principles of the Declaration of
Helsinki.
Exome Sequencing and Data Analysis
DNA extraction was performed with the Chemagic
DNA Blood Kit (Perkin Elmer, Waltham, MA,
USA) and fragmented using the M220 Sonicator
(Covaris, Woburn, MA, USA). Ligation of adapters
was performed according to the IDT-Illumina TruSeq
DNA Exome protocol (Illumina, San Diego, CA,
USA). Exome target regions were captured accord-
ing to the IDT-xGen hybridization capture of DNA
libraries protocol (Integrated DNA Technologies,
Coralville, IA, USA). Paired-end sequencing was
performed on the NextSeq 550 (Illumina). Align-
ment of reads to the human genome (GRCh37) and
variant calling was achieved by BaseSpace Onsite
(Illumina). The sequencing coverage for the entire
FOXC1 locus was 30 reads or higher (IDT-xGen
exome research panel version 1). For annotation
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of variants AlamutBatch version 1.10 (Interactive
Biosoftware, Rouen, France) was used. A gene list
containing core childhood glaucoma genes, as well as
additional candidate genes (selected through a liter-
ature search) was used for filtering of WES data in
all patients (Supplementary Material, Table S1). The
search for disease-associated variants was restricted
to listed genes and did not include analysis of WES
data. Variants with heterozygous allele frequency
(gnomAD heterozygous frequency all populations)
<1% and homozygous allele frequency (gnomAD
homozygous frequency all populations) <0.00001%
were considered (https://gnomad.broadinstitute.org/).
Synonymous and intronic variants were considered
if within 20 nucleotides proximity to the intron-exon
boundary. Missense variants were only considered if
predicted pathogenic by at least two algorithms.12
Copy number variations (CNVs) of genes within
the gene list were assessed using exome coverage
depth data (Sequence Pilot version 5.0; JSI Medical
Systems GmbH, Ettenheim, Germany). All identified
variants were submitted to ClinVar database (https:
//www.ncbi.nlm.nih.gov/clinvar/). Haplotype analysis
was performed according to previously published
single-nucleotide polymorphisms in CYP1B1.13,14
Segregation Analysis
All substitutions or indels identified through WES
were confirmed by Sanger sequencing, and avail-
able family members were sequenced for segregation
analysis (Supplementary Figs. S1–S7). Potential de
novo variants were confirmed by sequencing of
parental DNAand excluding nonpaternity. Polymerase
chain reaction (PCR) of CYP1B1 and FOXC1 was
performed on Veriti 96 Well Thermal Cycler (Applied
Biosystems, Waltham, MA, USA). The protocol
used for CYP1B1 amplification has previously been
published.15 PCR for FOXC1 was performed accord-
ing to PCR Phusion High-Fidelity DNA Polymerase
Protocol (Thermofisher Scientific, Waltham, MA,
USA) using the GC-buffer and 2x S-Solution (Solis
BioDyne, Tartu, Estonia). Big Dye Terminator Cycle
Sequencing Kit version 1.1/3.1 (Thermofisher Scien-
tific) was used for the Sanger reactions and a 3130xl
Genetic Analyzer (Applied Biosystems) performed
capillary sequencing. Sequences were visualized by
Chromas version 2.6.6 (Technelysium, Brisbane,
Australia). Primers are available on request. Multiplex
ligation-dependent probe amplification (MLPA) was
used to confirm FOXC1 CNVs using the SALSA
MLPA P054-B2 FOXL2-TWIST1 probemix (MRC
Holland, Amsterdam, The Netherlands) according
to the manufacturer’s instructions. MLPA ampli-
cons were analyzed using a 3130xl Genetic Analyzer
(Applied Biosystems) and Sequence Pilot version 5.0
(JSI medical systems).
Breakpoint Assessment
Breakpoints of CNVs were assessed using the
Infinium CytoSNP-850K BeadChip version 1.2
(Illumina). Data were aligned to the human reference
genome (GRCh38) by the BlueFuse Multi software
version 4.5 (Illumina).
Minigene Assay for Intronic Variant in
CYP1B1
A4715-bp fragment including all of exon 2, intron 2,
and exon 3 of CYP1B1was amplifiedwith TaKaRaLA
Taq polymerase (Takara Bio, Kusatsu, Japan) accord-
ing to the manufacturer’s instructions, using 20 ng of
genomic DNA. Primers were designed according to
the In-Fusion HD Cloning kit (Takara Bio). Ampli-
cons were inserted at the EcoRV restriction site of
pcDNA 3.1(+) vector (Thermofisher), and subsequent
transformation was performed according to the In-
Fusion HD cloning kit. Sequences of reference- and
variant-containing plasmid were verified by Sanger
sequencing of exon 2, 3, and 200 base pairs down- and
upstream of the exon-intron boundaries. HEK-293T
cells (Thermofisher) were plated at 5 × 105cells/well
in a six-well plate and transfected the following day
by branched Polyethylenimine (PEI; Mw ∼25 000;
Sigma-Aldrich, St. Louis, MO, USA). A total of
3 μg of plasmid DNA (2 μg of insert-containing
plasmid vector and 1 μg empty vector) was transfected
in a ratio PEI:DNA 3:1. Twenty hours after trans-
fection, total RNA was extracted using NuceloSpin
RNA plus Kit (Macherey-Nagel, Düren, Germany)
and subsequently converted into cDNA using the
SuperSript III Reverse Transcriptase (Thermofisher).
PCR on cDNA was performed, and products were
loaded on a 1% agarose gel. Real-time PCR was
performed using SYBR 2xMasterMix (Life Technolo-
gies, Carlsbad, CA, USA). Triplicates of each reaction
of 20 μL contained: 400 nmol/L primers and 100 ng
cDNA. Quantification was performed on ABI Prims
7900HT Fast Real-time Sequence Detection System
(Applied Biosystems) according to the manufacturer’s
instructions and analyzed using SDS2.2p1 software
(Thermofisher). Datawere normalized toRNAderived
from empty control plasmid. For statistical analysis
GraphPad PRISM version 6.07 (GraphPad Software,
San Diego, CA, ISA) was used.
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Figure 1. Pedigrees and segregation of CYP1B1 and FOXC1 pathogenic variants. All affected family members, as well as all unaffected
family members who were available for genetic testing, are shown (with the exception of family 6). The complete pedigrees are shown
in Supplementary Figures S9–S12. Sequence variations of CYP1B1 (families 1–4) are numbered to transcript NM_000104.3 and for FOXC1
(families 5–7) to transcript NM_001453.2. CN, copy number. †Manifests neither glaucoma nor features of Axenfeld-Rieger syndrome.
Results
Our cohort included 18 patients from 14 unrelated
families with bilateral childhood glaucoma (Table 2).
A diagnosis of PCG was made in 14 patients. Three
patients were diagnosed with glaucoma associated with
nonacquired ocular anomalies; two related patients
had ocular features of ARS, and one patient had a
Barkan membrane. One patient was diagnosed with
JOAG. Recessive variants in CYP1B1 and dominant
variants in FOXC1 were identified in 50% of the
families (Fig. 1). All of the listed variants (Table 1)
segregated with the disease and were classified as
disease-causing based on filtering criteria (see methods
sections) and previous reports. In eight patients (seven
families) no conclusively disease-causing variants were
identified, nor did we identify any heterozygous
variants in recessive childhood glaucoma genes.
Primary Congenital Glaucoma
Fourteen patients were diagnosed with PCG, of
which six (43%) harbored pathogenic variants in
CYP1B1, one (7%) a frameshift variant in FOXC1,
and seven (50%) remained without a genetic diagnosis.
All patients had typical features of PCG and received
trabeculotomy or fistulating surgeries with variable
clinical outcomes (Table 2). A novelCYP1B1 splice site
variant and previously reported pathogenic variants,
either in homozygosity or compound heterozygosity,
were identified in families 1 to 4 (Table 1). Consan-
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guinity was reported in only one (family 2) of the
two families with homozygous CYP1B1 variants. The
poor visual outcome of affected patients in family
2 may have been caused or exacerbated by the limited
access to medical care in their country of residence
during childhood. Review of the patient record in
patient 5 [II:1] harboring the FOXC1 frameshift
variant (NM_001453.2:c.697delT;p.(Cys233Alafs*82))
revealed dysmorphic facial features (midfacial hypopla-
sia) and a congenital heart defect (atrial septal defect
type 2), features also associated with ARS. A de novo
origin or mosaicism in the parents was found for the
CYP1B1 frameshift variant (NM_000104.3:c.535delG;
p.(Ala179Argfs*18)) in patient 1 [II:1] and the
FOXC1 frameshift variant in patient 5 [II:1]
(NM_001453.2:c.697delT;p.(Cys233Alafs*82))
(Supplementary Figs. S1 and S5).
Glaucoma AssociatedWith Nonacquired
Ocular Anomalies
Two related patients (family 6) diagnosed with
glaucoma associated with ARS harbored FOXC1
variations, and one patient (patient 13 [II:1]) with
glaucoma associated with a Barkan membrane
remained without a genetic diagnosis. Family 6
consisted of an affected father (patient 6 [I:1]) and
a daughter (patient 6 [II:1]) with mild iris hypopla-
sia, as well as iris-strands bridging the irido-corneal
angle (observed only in the father). Glaucoma was
diagnosed at the age of 10 years in the father. Because
the daughter had normal RNFL thickness and normal
perimetry, she was classified as a glaucoma-suspect
(Table 2). Genetic analysis revealed duplications of
FOXC1. According to microarray data (Infinium cyto-
850K BeadChip), the size of the duplicated region was
between 519 and 548 kb, including the duplication
of FOXQ1, FOXF2, and parts of GMDS, which are
flanking genes. The region was likely to be identical
to a previously reported duplication (Fig. 3C).16 An
additional missense variant (NM_001453.2:c.89C>T;
p.(Ala30Val)) co-segregated with the duplicated allele,
a finding that has not been described previously for
FOXC1 variants. According to coverage data analysis,
the variant was present only on one FOXC1 allele
(36% of reads contained the variant). Together with
the genetic results, a diagnosis of glaucoma associated
with ocular ARS features was made. No systemic
features of ARS were identified in family 6.
JOAG
Patient 7 [II:1] was diagnosed with JOAG at age
14 years. Genetic analysis revealed a FOXC1 duplica-
tion. Diagnosis was likely to have beenmade some time
after disease onset because of severe global develop-
mental delay. Marked optic atrophy was observed, but
with the exception of subepithelial corneal haze, the
anterior segment was normal. Despite several surgeries,
treatment had only limited success, and the patient was
legally blind (Table 2). Furthermore, patient 7 [II:1] had
dysmorphic facial features (prominent forehead, as well
as a protruding lower lip), features that may be associ-
ated with ARS. A novel FOXC1 duplication which
ranged between 366 to 406 kb in size and included
the duplication of neighboring genes FOXQ1, FOXF2,
and parts of GMDS was identified by genetic analy-
sis (Fig. 3C). His mother, in whom the duplication was
also detected, showed no evidence of ocular abnormal-
ity (including RNFL thickness and perimetry) apart
from subepithelial corneal haze comparable to that
observed in her son.
Minigene Assay for Novel CYP1B1 Variant
A novel CYP1B1 splice site variant
(NM_000104.3:c.1044-3C>G) identified in family 3
was functionally tested in a cellular system. Real-time
PCR from minigene assays revealed a 98% reduction
of correctly spliced CYP1B1 for the c.1044-3C>G
containing transcript compared to the reference (-
CT = 6.15 ± 1.13 SD, P = 0.0095) (Fig. 2C). Intron
retention was exclusively shown for the c.1044-3C>G
containing transcript and was verified by Sanger
sequencing (Fig. 2B, Supplementary Fig. S8). Inter-
estingly, the Human Splicing Finder score predicted
a 12.7% reduced acceptor function compared to the
reference sequence.
Discussion
In our Swiss cohort of 18 patients from 14 unrelated
families diagnosed with childhood glaucoma, WES
including CNV analysis revealed pathogenic variants
in CYP1B1 in four (29%) of the families; FOXC1
pathogenic variants or CNVs were detected in three
(21%) of the families. In seven families (50%), no
conclusively or potentially disease-causing sequence
variant was identified.
The ethnic heterogeneity of our cohort was
reflected by identification of pathogenic variants
in CYP1B1 previously found in Portuguese and
Moroccan (p.(Ala179Argfs*18)), Portuguese and
Spanish (p.(Glu387Lys)), Spanish and Turkish
(p.(Thr404Serfs*30)), Turkish (p.(Arg355Hisfs*69)),
Downloaded from tvst.arvojournals.org on 11/25/2020
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Figure 2. CYP1B1 variant c.1044-3C>G alters splicing in a minigene assay. (A) Scheme of minigene construction and position of forward
(F1) and reverse (R1) primer used for endpoint PCR. (B) Qualitative analysis (endpoint PCR): PCR plateau phase shows intron retention in
transcript containing the c.1044-3C>G variant compared to the reference. Additional bands represent alternative spliced transcript (1161
bp) and correctly spliced transcript (806 bp). p2, partial intron 2. †Nonsequenceable DNA-fragment. (C) Quantitative analysis (linear phase
PCR): Real-time PCR data representing fold difference of spliced transcript relative to reference. n, biological replicates; error bars represent
± SD; ** represents significance level according to Student’s t-test, P ≤ 0.01.
and Pakistani (p.(Leu487Pro)) patients.14,15,17–20 Inter-
estingly, the novel intronic variant c.1044-3C>G was
the only pathogenic variant found on the CCGCCG
haplotype, which, compared with the more common
ancestral CCGGTA haplotype, is less frequently
associated with pathogenic variants in CYP1B1
(Table 1).13,21 The intronic variant c.1044-3C>G
was the first CYP1B1 splice site variant function-
ally analyzed in a cellular system. Reduction of the
correctly spliced transcript by 98% compared to the
reference, as observed in our minigene assays, is most
likely to occur because of nonsense-mediated mRNA
decay induced by stop codons in the retained intron,
although this hypothesis remains untested. Because
the majority of CYP1B1 pathogenic variants reported
to date result in loss of function due to alterations in
protein stability, abundance, or enzymatic activity, we
assume that the reduced amount of correctly spliced
transcript in the presence of the c.1044-3C>G variant
is disease-causing.22,23
Clinical manifestations were consistent with
features of PCG in all patients with pathogenic
CYP1B1 variants. Several studies have attempted
to compare the clinical phenotype and genotype in
PCG patients with and without pathogenic variants
in CYP1B1; however, results to date are inconclu-
sive.17,24,25 More promising is the approach taken by
Hollander et al.26 and García-Antón et al.,22 namely
assessing the histologic angle tissue and enzyme activ-
ity. Their results suggest that CYP1B1 null alleles
lead to an underdeveloped post-trabecular outflow
pathway, making these patients more suitable candi-
dates for fistulating rather than nonfistulating surgery.
In keeping with this, patient 1 [II:1] (harboring two
null alleles) had undergone fistulating surgeries on
both eyes; however, without success in the right eye
and with only qualified success in the left eye. The
small sample size and variable follow-up period make
a meaningful genotype-phenotype correlation between
the patients with and without pathogenic CYP1B1
variants within our cohort challenging. However,
concordant with findings in Saudi Arabian families,
more frequent postoperative complications and lower
treatment success rates were apparent in the patients
with, compared to those without, pathogenic CYP1B1
variants (Table 2).24
Patients carrying FOXC1 variants showed consid-
erable inter- and intrafamilial variability of clinical
manifestations. These ranged from subepithelial haze
in patients 7 [I:2, II:1], JOAG in patient 7 [II:1],
iris hypoplasia and glaucoma in patients 6 [I:1, II:1],
and PCG in patient 5 [II:1]. FOXC1 is a member of
forkhead box family transcription factors involved in
the formation of the anterior segment.27 The whole
range of gene alterations has been described as causes
of autosomal dominant anterior segment defects,
often classified as part of the ARS-spectrum.27–30 A
dosage-dependent mechanism for phenotype variabil-
ity has been described previously.31,32 According to this
model, variants displaying 50% to 60% or 130% to
150% of transcriptional activity result in goniodysge-
nesis associated with glaucoma, whereas activity levels
beyond these thresholds lead to more severe anterior
segment anomalies and nonocular tissue involvement
(resulting in systemic features such as sensorineu-
ral hearing loss, congenital heart defects, dysmor-
phic features, intellectual disability, and dental and
umbilical anomalies). FOXC1 duplications, presumed
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Figure 3. FOXC1 variants associatedwith childhood glaucoma. (A) Missense and de novo frameshift variants identified by exome sequenc-
ing. Thirty-six percent of reads contain themissense variant c.89C>T. (B) Location of identified variants within FOXC1. Scheme adapted from
Medina-Trillo et al.31 (C) Extent of segmental duplications shown in a schematic representation of partial chromosome 6p25. Shaded areas
indicate breakpoint regions. Scheme adapted from Chanda et al.16
to have 150% of transcriptional activity, are concor-
dant with this proposal, as carriers have previously
been shown to develop glaucoma.28 Our findings are
also largely consistent with this model, as FOXC1
duplication carriers (patients 6 [I:1, II:1] and 7 [I:2,
II:1]) had less severe ocular phenotypes compared with
patient 5 [II:1] carrying the de novo frameshift variant
p.(Cys233Alafs*82), who presented with congenital
onset glaucoma, congenital heart defect, and midfacial
hypoplasia. The frameshift variant p.(Cys233Alafs*82)
results in a protein lacking part of the inhibition
domain (Fig. 3B). Such variants may reveal increased
(over 150%) transcriptional activation despite reduced
stability of the protein, according to Medina-Trillo et
al.31 Our findings in patient 5 [II:1] confirm the associ-
ation of frameshift variants located in the inhibition
domain with a congenital glaucoma phenotype and
additional extraocular findings.33,34 FOXC1 duplica-
tions were previously associated with iris hypoplasia
and glaucoma, yet patient 7 [II:1] had a macroscop-
ically normal iris stroma. In addition, patient 7 [II:1]
showed global developmental delay and a prominent
forehead, as well as a protruding lower lip, features
associated with ARS but not previously described
for FOXC1 duplications.28 Genetic alterations other
than FOXC1 duplication cannot be excluded as a
cause for the developmental delay. The absence of
glaucoma and typical ocular ARS-features in the 54-
year-old mother of patient 7 [II:1] is unexpected
because high penetrance of ocular findings has been
postulated for ARS in general, as well as for FOXC1
duplications.28,29,35 In mice, penetrance of clinical
abnormalities was shown to depend on the genetic
background, which may explain (among other factors)
variable disease severity and penetrance in humans.36
Furthermore, the pathogenicity of duplicated FOXQ1,
FOXF2, and parts of GMDS remains elusive, and
their role in embryonic development should be eluci-
dated by further investigation.37 It remains unknown
whether the mother harbors additional genetic varia-
tions that somehow act as protecting factors. Further-
more, although there is a strong indication for FOXC1
duplications being pathogenic, the possibility of a
linked locus harboring the actual disease-causing alter-
ation cannot be excluded. The two families in our
cohort carrying FOXC1 duplications add to cases
of FOXC1-associated Axenfeld-Rieger spectrum with
development of glaucoma at a young age, whereas
patient 5 [II:1] with the frameshift variant may be
classified as a “FOXC1-associated primary congenital
glaucoma or as “ARS with PCG”.4
The prevalence of CYP1B1 pathogenic variants in
our cohort was comparable to other European popula-
tions.17,19,38 Previous studies investigated the preva-
lence of FOXC1 pathogenic variants among child-
hood glaucoma patients.34,39,40 Siggs et al.34 recently
analyzed a large Italian-Australian cohort of PCG
patients without CYP1B1 variants, and found 6.1% of
disease-causing FOXC1 variants among these patients.
In our study, the respective percentage is higher
(14%; one of seven PCG families without a CYP1B1
variant). In general, it needs to be acknowledged that
exome sequencing cannot reliably identify all forms of
genetic variation (e.g. deep intronic variants, structural
variants including copy number variants in noncod-
ing regions), and that this may explain a proportion
of unsolved cases in studies like ours using WES as a
diagnostic approach.41
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Our findings highlight the need for routine imple-
mentation of genetic testing in affected patients in
Switzerland. Although the relatively small cohort size
is a limiting factor of the study, our results suggest that
Sanger sequencing of the entire CYP1B1 and FOXC1
genes complemented by MLPA of FOXC1 should
be performed as a first genetic diagnostic workup
in patients presenting with childhood glaucoma in
Switzerland, before the use of extended gene panels.
In cases of dominant pedigrees only FOXC1 may be
tested, whereas in sporadic cases both CYP1B1 and
FOXC1 should be tested given the occurrence of de
novo FOXC1 variants. However, if disease onset is
after the age of four years, and additional acquired or
nonacquired ocular anomalies are lacking, testing may
include the JOAG gene MYOC, despite the fact that
no pathogenic variants in this gene were recorded in
our cohort. Further, if detailed phenotype assessment
reveals distinct nonacquired ocular anomalies such as
ectopia lentis, aniridia, cataract, or Peters’ anomaly,
screening should be extended to additional disease-
associated genes. Thus clinical diagnosis should guide
genetic testing. However, it is important to emphasize
that in patients carrying FOXC1 pathogenic variants
a specific review of systemic features of ARS should
be made. Finally, sharing of clinical and genetic data
on international childhood glaucoma registries like
the Childhood Glaucoma Research Network may be
recommended to further accelerate research in the field
of childhood glaucoma.2
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